Pure Global
NCT06304922

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

Assiut University·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer
Study type
Observational
Intervention type
behavioral
Sponsor & location
Primary sponsor
Assiut University
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Apr 01, 2026
Enrollment
45 participants
Primary outcome

Objective response rate.,Progression free survival

Summary

The main objective of this prospective study is to assess the clinical outcomes of platinum
 based chemotherapy cases either cisplatin or carboplatin according to BRCA status in
 neoadjuvant and recurrent ovarian cancer.

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06304922
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06304922 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.